Advances in Treatment of Frontotemporal Dementia

Guimet, Nahuel Magrath; Zapata-Restrepo, Lina M.; Miller, Bruce L.

doi:10.1176/appi.neuropsych.21060166

Cited by 27 publications

(22 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Des antidépresseurs (comme la trazodone) peuvent atténuer les symptômes comportementaux. Des antipsychotiques sont indiqués chez les personnes qui présentent des comportements dangereux, mais doivent autrement être évités, en raison de leurs effets indésirables 5 . L’efficacité des stratégies non pharmacologiques pour la maîtrise des symptômes est limitée.…”

Section: On Ne Peut Pas Modifier L’évolution De La Démence Frontotemp...unclassified

Démence frontotemporale

Medina-Rioja,

Gonzalez-Calderon,

Masellis

2024

CMAJ

View full text Add to dashboard Cite

Section: On Ne Peut Pas Modifier L’évolution De La Démence Frontotemp...unclassified

Démence frontotemporale

Medina-Rioja,

Gonzalez-Calderon,

Masellis

2024

CMAJ

View full text Add to dashboard Cite

“…The occurrence of neuropsychiatric disorders is increasing day by day, 293 but there are limitations in diagnosis, 294 , 295 limited means of treatment, and unsafe drugs. 296 , 297 , 298 Naturally derived biological humoral exosomes possess specific biomolecules that can be used as a “signature” of parent cells to reflect changes in their contents under pathological conditions.…”

Section: Conclusion and Prospectsmentioning

confidence: 99%

Exosomes in brain diseases: Pathogenesis and therapeutic targets

Pang

et al. 2023

MedComm

View full text Add to dashboard Cite

Exosomes are extracellular vesicles with diameters of about 100 nm that are naturally secreted by cells into body fluids. They are derived from endosomes and are wrapped in lipid membranes. Exosomes are involved in intracellular metabolism and intercellular communication. They contain nucleic acids, proteins, lipids, and metabolites from the cell microenvironment and cytoplasm. The contents of exosomes can reflect their cells’ origin and allow the observation of tissue changes and cell states under disease conditions. Naturally derived exosomes have specific biomolecules that act as the “fingerprint” of the parent cells, and the contents changed under pathological conditions can be used as biomarkers for disease diagnosis. Exosomes have low immunogenicity, are small in size, and can cross the blood–brain barrier. These characteristics make exosomes unique as engineering carriers. They can incorporate therapeutic drugs and achieve targeted drug delivery. Exosomes as carriers for targeted disease therapy are still in their infancy, but exosome engineering provides a new perspective for cell‐free disease therapy. This review discussed exosomes and their relationship with the occurrence and treatment of some neuropsychiatric diseases. In addition, future applications of exosomes in the diagnosis and treatment of neuropsychiatric disorders were evaluated in this review.

show abstract

“…These genetic mutations are believed to disrupt critical cellular processes, eventually leading to neuronal cell death. Despite significant progress in understanding the genetic underpinnings of FTD, the development of effective therapies remains challenging [6]. In recent years, microRNAs (miRs) have emerged as important players in the molecular mechanisms underlying neurodegenerative diseases [7].…”

Section: Introductionmentioning

confidence: 99%

A role for astrocytic miR-129-5p in Frontotemporal Dementia

Kaurani,

Pradhan,

Schröder

et al. 2024

Preprint

View full text Add to dashboard Cite

Frontotemporal dementia is a debilitating neurodegenerative disorder characterized by frontal and temporal lobe degeneration, resulting in behavioral changes, language difficulties, and cognitive decline. In this study, smallRNA sequencing was conducted on postmortem brain tissues obtained from FTD patients with GRN, MAPT, or C9ORF72 mutations, focusing on the frontal and temporal lobes. Our analysis identified miR-129-5p as consistently deregulated across all mutation conditions and brain regions. Functional investigations revealed a novel role of miR-129-5p in astrocytes, where its loss led to neuroinflammation and impaired neuronal support functions, including reduced glutamate uptake. Depletion of miR-129-5p in astrocytes resulted in the loss of neuronal spines and altered neuronal network activity. These findings highlight miR-129-5p as a potential therapeutic target in neurodegenerative diseases and also sheds light on the role of astrocytes in Frontotemporal dementia pathogenesis.

show abstract

Advances in Treatment of Frontotemporal Dementia

Cited by 27 publications

References 128 publications

Démence frontotemporale

Démence frontotemporale

Exosomes in brain diseases: Pathogenesis and therapeutic targets

A role for astrocytic miR-129-5p in Frontotemporal Dementia

Contact Info

Product

Resources

About